Posted by Michael Wonder on 01 May 2026
MRM Health’s lead candidate MH002 granted fast track designation by US FDA for the treatment of mild to moderate ulcerative colitis
30 April 2026 - MRM Health today announced that MH002, the Company’s lead rationally designed live biotherapeutic product candidate, has been granted Fast Track designation by the US FDA for the treatment of mild to moderate ulcerative colitis.
MH002 today is the most advanced live biotherapeutic product targeting inflammatory bowel disease-specific mechanisms and is composed of a rationally designed microbial consortium of six well characterised commensal strains.
